In melanoma models, DAC cooperates with IL- 12 [22], type I IFNs [20] or ICAM-1 antibody drug conjugates [23] to promote anti-tumor efficacy by sensitizing to direct tumor killing and by remodeling the TME. Here, ICAM1 is linked to neoplasm.